Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.
Learn how we enable lead candidate down-selection in 1 day by performing functional characterization during primary screening. Case studies highlight how our customers are dramatically accelerating development of next-generation antibody therapeutics.
Watch a 1-hour webinar from the 2018 Antibody Engineering & Therapeutics Digital Week titled, “Emerging Technologies for Finding Rare Antibodies,” featuring scientists from Berkeley Lights and Teva Pharmaceuticals.
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows Pharma to succeed against difficult targets and deliver best-in-class antibody therapeutics.